Ambrx Biopharma Inc. (AMAM)
|52 Week Range||6.55-16.285|
|1y Target Est||-|
|DCF Unlevered||AMAM DCF ->|
|DCF Levered||AMAM LDCF ->|
|Debt / Equity||4.34%||Neutral|
Upgrades & Downgrades
Latest AMAM news
Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data
24 October 2023
Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology fo...
Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data
23 October 2023
Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. In order to see if ARX517 can be improved upon for ...
Why Shares of Ambrx Biopharma Soared This Week
21 September 2023
The company, formerly based in the Cayman Islands, is moving to Delaware. It is expected to announce trial data next week regarding two of its lead therapies.
Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences
5 September 2023
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, wi...
Is Ambrx Biopharma (AMAM) Outperforming Other Medical Stocks This Year?
23 August 2023
Here is how Ambrx Biopharma Inc. Sponsored ADR (AMAM) and Sientra (SIEN) have performed compared to their sector so far this year.
Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ES...
28 July 2023
Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting Presentations represent the first time clinical data regarding ARX517 will be presented at ...
Ambrx to Present at Multiple Upcoming Investor Meetings
30 May 2023
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, w...
Ambrx Biopharma: ARX788's Potential In Cancer Treatment Presents Promising Opportunity
20 May 2023
Ambrx Biopharma's stock value has surged due to positive preliminary data from cancer-targeting clinical trials of ARX788 and ARX517. With cash reserves increasing to $149.6 million in Q1 2023, Ambrx ...
Why Shares of Ambrx Biopharma Jumped This Week
18 May 2023
Ambrx's lead therapies target breast cancer and prostate cancer, two of the most common forms of cancer. The company has enough cash, it said, to fund operations for another year.